Publication:
Point-of-care detection of SARS-CoV-2 antigen among symptomatic vs. asymptomatic persons: Testing for COVID-19 vs. infectivity.

dc.contributor.authorNeukam, Karin
dc.contributor.authorLucero, Alicia
dc.contributor.authorGutiérrez-Valencia, Alicia
dc.contributor.authorAmaya, Lucas
dc.contributor.authorEchegoyen, Natalia
dc.contributor.authorMartelli, Antonella
dc.contributor.authorVidela, Cristina
dc.contributor.authorDi Lello, Federico A
dc.contributor.authorMartínez, Alfredo P
dc.date.accessioned2023-05-03T13:45:36Z
dc.date.available2023-05-03T13:45:36Z
dc.date.issued2022-10-17
dc.description.abstractManagement of the coronavirus disease 2019 (COVID-19) pandemic caused by a novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requires rapid and simple methods to detect COVID-19 patients and identify potential infectors. This study aimed to evaluate the utility of a point-of-care (PoC) rapid antigen diagnostic test (Ag-RDT) in these settings. Individuals who consecutively presented for SARS-CoV-2 testing at a tertiary care center in Buenos Aires, Argentina, underwent PoC Ag-RDT testing and real-time RT-PCR (qRT-PCR) on the same day during June 2021. Of 584 included subjects, 108 (18.5%) were symptomatic for COVID-19 while the remaining presented for miscellaneous reasons unrelated to possible or confirmed contact with a SARS-CoV-2-infected individual. A positive Ag-RDT result was obtained in 26 (24.1%) symptomatic and 7 (1.5%) asymptomatic persons (p PoC Ag-RDT accurately detected active SARS-CoV-2 infection and showed acceptable diagnostic performance in asymptomatic persons potentially spreading infectious virus. Ag-RDT may therefore be useful to slow down or stop transmission by enabling adequate decisions on isolation at a public health level.
dc.identifier.doi10.3389/fpubh.2022.995249
dc.identifier.essn2296-2565
dc.identifier.pmcPMC9619045
dc.identifier.pmid36324442
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619045/pdf
dc.identifier.unpaywallURLhttps://www.frontiersin.org/articles/10.3389/fpubh.2022.995249/pdf
dc.identifier.urihttp://hdl.handle.net/10668/20741
dc.journal.titleFrontiers in public health
dc.journal.titleabbreviationFront Public Health
dc.language.isoen
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.page.number995249
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCOVID-19
dc.subjectPCR
dc.subjectSARS-CoV-2
dc.subjectpoint-of-care
dc.subjectpublic health
dc.subjectrapid antigen testing
dc.subjectsurveillance
dc.subjectviral kinetics
dc.subject.meshHumans
dc.subject.meshCOVID-19
dc.subject.meshSARS-CoV-2
dc.subject.meshCOVID-19 Testing
dc.subject.meshPoint-of-Care Systems
dc.subject.meshRNA, Viral
dc.subject.meshSensitivity and Specificity
dc.titlePoint-of-care detection of SARS-CoV-2 antigen among symptomatic vs. asymptomatic persons: Testing for COVID-19 vs. infectivity.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number10
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC9619045.pdf
Size:
444.76 KB
Format:
Adobe Portable Document Format